Study Results: RepliCel’s RCT-01 Tendon Repair Clinical Trial

Six-month results from Phase I/II study indicate that RepliCel's RCT-01 fibroblasts demonstrated product safety and clinical potential for tendon regeneration and healing, with no adverse events.

All treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period with no response to standard...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us